Your Patient Has a Prescription. Now They Need the Medication.

You've made the clinical decision to prescribe Rifaximin (Xifaxan). The patient understands the plan. They leave your office — and then the calls start coming in. "My pharmacy doesn't have it." "They said it'll take a week to order." "Insurance denied it."

For a medication that's been on the market since 2004, Xifaxan remains remarkably difficult for patients to access. As the prescribing provider, you're often the first person they turn to when the system fails them. This guide offers practical steps your practice can take to reduce those friction points.

Current Availability: What You Need to Know

Xifaxan is not in a formal FDA-listed shortage as of February 2026. Salix Pharmaceuticals (Bausch Health) remains the sole manufacturer, and production appears to be stable.

The access issue is economic, not manufacturing-based:

• Cash price: $1,600–$2,200/month for HE maintenance; $1,400–$1,800 per IBS-D course
• No generic available — patent exclusivity projected through 2028–2029
• Pharmacy stocking: Many retail pharmacies don't carry Xifaxan routinely due to the high unit cost and risk of unsold inventory
• Payer restrictions: Prior authorization and step therapy requirements are near-universal

Why Patients Can't Find It

Understanding the bottlenecks helps you troubleshoot more effectively:

Pharmacy-Level Barriers

Most retail pharmacies operate on thin margins. Stocking a medication that costs $1,600+ per bottle — with the risk that insurance may deny the claim — doesn't make financial sense unless they have a guaranteed buyer. Result: Xifaxan is often "available to order" but not on the shelf.

Insurance-Level Barriers

The majority of commercial plans and Medicare Part D formularies place Xifaxan on Tier 3 or specialty tier with mandatory prior authorization. For HE, many require documented Lactulose trial. For IBS-D, step therapy may require failure of dietary modifications or OTC agents. PA processing takes 1–14 days depending on the payer.

Patient-Level Barriers

High copays (often $200–$500/month even with insurance) lead to prescription abandonment. Patients may not fill the prescription and not report this back to you, creating a gap in therapy that only surfaces at the next visit — or in the ER.

What Providers Can Do: 5 Actionable Steps

Step 1: Submit Prior Authorization Proactively

Don't wait for the pharmacy to trigger a PA denial. Submit authorization with the initial prescription. Include:

• ICD-10 codes (K72.x for HE, K58.0 for IBS-D, K90.49 for SIBO if applicable)
• Documentation of prior treatments trialed
• Clinical justification for Rifaximin specifically
• Recent labs or procedure notes supporting the diagnosis

Many EHR systems support electronic PA submission. Assign a trained staff member to manage the PA workflow for high-cost medications.

Step 2: Direct Patients to the Right Pharmacy

Before the patient leaves your office, help them identify a pharmacy that's likely to have Xifaxan or can obtain it quickly:

• Use Medfinder to check real-time pharmacy stock in the patient's area
• Specialty pharmacies are more likely to carry Xifaxan and may be required by certain insurance plans
• Mail-order pharmacy through the patient's insurance plan bypasses local stock issues entirely
• Hospital outpatient pharmacies often carry high-cost medications that retail pharmacies avoid

Step 3: Connect Patients with Savings Programs

Cost is the single biggest barrier to Xifaxan access. Make sure every patient knows about:

• Xifaxan Copay Savings Card: Eligible commercially insured patients may pay $0. Download at xifaxan.copaysavingsprogram.com or call 1-866-XIFAXAN.
• Bausch Health Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients.
• PAN Foundation: Copay assistance for patients with financial need, including those on Medicare.

Consider keeping printed information about these programs in your office or embedding links in your after-visit summary. For a comprehensive cost guide to share with patients: How to save money on Xifaxan.

Step 4: Maintain a Bridge Supply

If your practice receives Xifaxan samples from manufacturer representatives, maintain a small supply specifically for bridging therapy during PA delays or pharmacy ordering periods. Even a 7–14 day supply can prevent an HE episode or keep an IBS-D patient on track.

Track sample distribution carefully for compliance and documentation purposes.

Step 5: Have a Documented Backup Plan

For every patient on Xifaxan, document a clear contingency plan in the chart for therapy interruptions:

• HE patients: Optimize Lactulose dose (titrate to 2–3 soft stools/day). Consider short-term Neomycin if Lactulose alone is insufficient. Monitor for cognitive changes.
• IBS-D patients: Loperamide for symptom management. Consider Eluxadoline (if appropriate) or low-dose TCA for visceral pain. Dietary review (low-FODMAP).
• SIBO patients: Metronidazole or Amoxicillin-clavulanate as alternative antibiotics.

A documented backup plan ensures continuity even if a different provider sees the patient during a gap.

Alternatives to Consider

While Xifaxan is clinically unique as a non-absorbable gut-targeted antibiotic, several alternatives exist depending on the indication:

• Lactulose: First-line for HE, $15–$60/month, universally available
• Neomycin: HE alternative with nephrotoxicity/ototoxicity concerns for long-term use
• Eluxadoline (Viberzi): IBS-D, mu-opioid agonist, contraindicated without gallbladder
• Alosetron (Lotronsa): Severe IBS-D in women, restricted prescribing program
• Metronidazole: Off-label SIBO treatment, widely available generic

For a detailed comparison, see: Alternatives to Xifaxan.

Workflow Tips for Your Practice

• Flag Xifaxan prescriptions in your EHR for automatic PA submission
• Create a Xifaxan resource sheet with savings program links, pharmacy contacts, and alternative medication options to hand to patients
• Follow up at 7 days after prescribing to confirm the patient filled the prescription — early identification of access barriers prevents clinical deterioration
• Bookmark Medfinder for Providers for real-time pharmacy availability checks during appointments
• Designate a team member as the point person for high-cost medication access issues

Final Thoughts

The gap between prescribing Xifaxan and a patient actually taking it is wider than it should be. But with proactive PA management, the right pharmacy channels, savings program enrollment, and clear backup plans, your practice can significantly improve fill rates and therapy continuity.

Tools like Medfinder are designed to make this easier — for both you and your patients. For the broader supply picture, see our Xifaxan shortage briefing for providers.